Kidney Cancer Drugs, Surgery, Targeted Therapy, Immunotherapy, or a Combination of These Treatments Play Major Role in Kidney Cancer Treatment
Kidney cancers are also called renal tumors. There are various kinds of kidney cancers including renal cell carcinoma, renal tumor, adenocarcinoma, renal pelvis carcinoma, squamous cell carcinoma and transitional cell carcinoma. Most kidney cancer is common in men, and more so in elderly people. However, it can also be found in women. In the U.S., about 73,750 new cases of kidney cancer (45,520 in men and 28,230 in women) will be diagnosed and about 14,830 people (9,860 men and 4,970 women) will die from this disease, in 2020, according to The American Cancer Society’s most recent estimates.
Surgery, targeted therapy, immunotherapy, or a combination of these treatments play a major role in kidney cancer treatment. One of the popular kidney cancer drugs in the emerging markets is Arava, an acronym for avermectine, atovaquone and vincristine. Avastin, also a prescription medicine, is suggested to treat acute flaccid kidney cancer, especially when it does not respond to other drug therapy. It is taken in combination with bevacizumab, a newly approved drug. Like Arava, bevacizumab has been approved for treating adult kidney cancer, but with varied results. In addition, another drug called gemcitabine is sometimes given along with avastin for faster effects.
Another promising new kidney cancer drug in the emerging markets is periactinib, a chemical drug that is usually given in tablet form. This drug targets cyclosporine, an amino acid that is believed to cause kidney cancer. Bicalutamide, an anti-androgen drug, is a promising compound that acts against the formation of prostate cancer cells. Similarly, chemical drugs like Aldactone, Leupeptine, Flotrimazole, and Methotrexate are also used for the treatment of prostate cancer. Chemotherapy, a highly successful treatment, is generally used in the advanced stage of cancer to ensure that the disease is not spread to other parts of the body.
Another promising new kidney cancer drugs are the combination of inhibitors and antioxidants called angiogenesis inhibitors. These inhibitors inhibit the production of new blood vessels formed by the proliferation of malignant cells. As the malignant cells grow in number, they produce blood clots. Antioxidants neutralize these clots, removing them from the area where they have grown. The combination of these two important products has the aim of reducing the size of the clots that would then pass through the urethra into the bladder or urinary tract.
Comments
Post a Comment